n-HA/PA66复合生物活性融合器在颈椎病前路减压融合术中的初步应用研究

分析52例颈椎病行前路减压、n-HA/PA66复合生物活性融合器植骨、钛钉板系统内固定颈椎前路重建手术患者的临床资料,探讨自行研制的纳米羟基磷灰石/聚酰胺66(n-HA/PA66)复合生物活性融合器在颈椎病前路减压固定融合手术中的初步临床疗效。所有术后均获得6～25个月(平均13个月)的随访。患者术前症状均得到改善,JOA评分术前平均为10.4分,术后为15.7分。n-HA/PA66复合生物活性融合器于术后3～6个月骨性融合。颈椎生理曲度、椎间高度、颈椎稳定性均维持良好。无融合器下沉、塌陷、移位发生,无感染、内固定物松动、脱落、断裂等并发症。n-HA/PA66复合生物活性融合器能有效重建和维持颈椎体的结构和高度,可能是一种理想的颈椎植骨替代材料。     

多功能充气式介入术后上肢垫的设计与应用

经桡动脉行冠状动脉造影(CAG)术后使用弹力绷带进行加压止血,患者手腕经常出现肿胀、疼痛、麻木等症状,而使用上肢垫抬高肢体有利于促进静脉回流,减轻症状,但是,临床以往使用的上肢垫存在种种弊端,无法满足使用需求。该研究设计了一种多功能充气式介入术后上肢垫,用于经桡动脉行CAG术后抬高、制动、冷敷术肢,可以缓解术肢肿胀、疼痛,减少皮下出血,提高患者的舒适度。     

Hypertension and Associated Risk Factors among Children with Intellectual Disability: A Cross-Sectional Study

To investigate the prevalence of hypertension and associated risk factors in Chinese children with intellectual disability, a cross-sectional study was conducted in a sample of 558 children with intellectual disability aged 6–18 years in Hong Kong, and 452 (81.0%) with valid data were included in the data analysis. Blood pressure was measured according to a standard protocol. Hypertension was defined using the age-, gender-, and height-specific classification criteria recommended by the 2018 Chinese Guidelines for Children. Multivariate and hierarchical logistic regression was fitted to examine the associations of hypertension with potential risk factors. Overall, 31.4% of the participants were classified as having hypertension. Obese children were more likely to develop hypertension than non-obese children (adjusted OR = 2.77, 95% CI: 1.28, 5.99, p = 0.010). A paternal education of college or above and a paternal occupation of clerks, sales representatives, and workers were also associated with an increased risk of hypertension. The prevalence of hypertension is high among Chinese children with intellectual disability. Obesity was the strongest risk factor. Further longitudinal studies are warranted to confirm our findings. Nevertheless, preventions against obesity are promising to receive doubled benefits in reducing both obesity and hypertension, given its strong relationship with hypertension in this special population.     

Neonatal clavicular fracture: clinical analysis of incidence, predisposing factors, diagnosis, and outcome

The objective of this study is to identify maternal, perinatal, and fetal risk factors for clavicular fracture in a single institution. We performed a prospective study of all deliveries during a 14-month period to identify confirmed cases of neonatal clavicular fracture. The control group consisted of the deliveries immediately preceding and following the index cases. Fifty-three cases of clavicular fracture were identified among the 4789 deliveries from October 1995 through November 1996 for an incidence of 1.11%. Three neonates in the clavicular fracture group were delivered through cesarean section. Neonates with fracture were significantly heavier at birth than those without (3564 vs. 3283 g, p <0.001), and had a lower mean head-to-abdominal circumference ratio (0.93 vs. 1.08, p <0.001), history of giving birth to a macrosomia (21 vs. 4%, p <0.05). The anterior shoulder was the predominant site of fracture (30/53). Fracture was detected mostly during the first 3 days of neonatal life (46/53). The outcome was benign, with complete recovery in all cases and no associated neurological sequelae. Neonatal clavicular fracture tended to be associated with neonatal somatometric characteristics and difficult deliveries. Considering the benign nature of this birth trauma, more invasive intrapartum management to lower its incidence is not advised.     

The impact of alfentanil supplementation on the sedation of bronchoscopy: A meta-analysis of randomized controlled trials

Background:The efficacy of alfentanil supplementation for the sedation of bronchoscopy remains controversial. We conduct a systematic review and meta-analysis to explore the influence of alfentanil supplementation on the sedation during bronchoscopy.Methods:We search PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through December 2019 for randomized controlled trials (RCTs) assessing the effect of alfentanil supplementation versus placebo for the sedation during bronchoscopy. This meta-analysis is performed using the random-effect model.Results:Five RCTs are included in the meta-analysis. Overall, compared with control group for bronchoscopy, alfentanyl supplementation is associated with significantly reduced coughing scores (Std. MD = –0.55; 95% CI = –0.96 to –0.14; P = 0.009) and dose of propofol (Std. MD = –0.34; 95% CI = –0.64 to –0.04; P = 0.03), but reveals the increase in hypoxemia (RR = 1.56; 95% CI = 1.17 to 2.08; P = 0.002).Conclusions:Alfentanyl supplementation benefits to reduce coughing scores and dose of propofol for bronchoscopy, but increases the incidence of hypoxemia. The use of alfentanyl supplementation for bronchoscopy should be with caution.     

Ferric citrate for the treatment of hyperphosphatemia and anemia in patients with chronic kidney disease: a meta-analysis of randomized clinical trials

BackgroundHyperphosphatemia and anemia, which are common complications of chronic kidney disease (CKD), can independently contribute to cardiovascular events. Several previous studies have found that the iron-based phosphate binder, ferric citrate (FC), could be beneficial to both hyperphosphatemia and anemia.MethodsRelevant literature from PUBMED, EMBASE, the Cochrane Central Register of Controlled Trials (CCRCT) and MEDLINE databases were searched up to 21 February 2022, in order to conduct a meta-analysis to investigate the efficacy, safety and economic benefits of ferric citrate treatment in CKD patients with hyperphosphatemia and anemia. The meta-analysis was conducted independently by two reviewers using the RevMan software (version 5.3).ResultsIn total, this study included 16 randomized clinical trials (RCT) involving 1754 participants. The meta-analysis showed that ferric citrate could significantly reduce the serum phosphorus in CKD patients compared to the placebo control groups (MD −1.76 mg/dL, 95% CI (−2.78, −0.75); p = 0.0007). In contrast, the difference between ferric citrate treatment and active controls, such as non-iron-based phosphate binders, sevelamer, calcium carbonate, lanthanum carbonate and sodium ferrous citrate, was not statistically significant (MD − 0.09 mg/dL, 95% CI (−0.35, 0.17); p = 0.51). However, ferric citrate could effectively improve hemoglobin levels when compared to the active drug (MD 0.43 g/dL, 95% CI (0.04, 0.82); p = 0.03) and placebo groups (MD 0.39 g/dL, 95% CI (0.04, 0.73); p = 0.03). According to eight studies, ferric citrate was found to be cost-effective treatment in comparison to control drugs. Most of the adverse events (AE) following ferric citrate treatment were mild at most.ConclusionCollectively, our review suggests that iron-based phosphate binder, ferric citrate is an effective and safe treatment option for CKD patients with hyperphosphatemia and anemia. More importantly, this alternative treatment may also less expensive. Nevertheless, more scientific studies are warranted to validate our findings.     

碘苯酯肝动脉栓塞的动物实验

用健康杂种小猪进行碘苯酯肝动脉栓塞(hepatic arterial embolization,简称HAE),探讨碘苯酯肝动脉栓塞的有关并发症及相对危险性。结果表明,碘苯酯可以进入肺循环产生肺油栓,并引起相应病理改变,甚至致死,还可以引起正常肝组织梗死,在梗死区较长时间残留,甚至产生X线的假肿瘤征象。     

Pathological outcomes in men with prostate cancer who are eligible for active surveillance

Background

In order to prevent over treatment of prostate cancer and significant adverse effects after surgical intervention, active surveillance was suggested in low risk or very low risk patients. This study aimed to retrospectively analyze the adverse pathological results of candidates eligible for active surveillance.

RP-HPLC法同时测定橘叶中3个黄酮类成分的含量

目的:建立同时测定橘叶中川陈皮素、橘红素、5-去甲川陈皮素含量的反相高效液相色谱法。方法:采用Kromasil C18(250 mm×4.6 mm,5μm)色谱柱,流动相为甲醇-乙腈-水(体积比30∶30∶40),流速1.0 mL.min-1,检测波长342 nm;柱温为室温(25℃)。结果:川陈皮素、橘红素、5-去甲川陈皮素线性范围分别为0.239～2.870μg(r=0.9995),0.102～1.224μg(r=0.9995),0.054～0.643μg(r=0.9995);平均回收率(n=6)分别为98.06%,98.02%,97.61%,RSD分别为2.6%,1.9%,2.0%。结论:本法快速、简便、准确,重复性好,可用于橘叶川陈皮素、橘红素、5-去甲川陈皮素的定量分析和质量控制。